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Objectives: Enzalutamide prolonged overall survival and radiographic progres-
sion-free survival (rPFS), delayed initiation of cytotoxic chemotherapy and main-
tained quality of life in patients with chemotherapy-naïve mCRPC after failure of 
ADT (PREVAIL; Beer et al 2014). The cost-effectiveness of enzalutamide, compared 
with abiraterone plus prednisone (ABI+P) for patients with chemotherapy-naïve 
mCRPC, was evaluated from the perspective of the Canadian Ministries of Health 
(MoH). MethOds: A Markov model was developed to capture time spent by patients 
in various health states: stable, progression and death. Results were reported as 
incremental costs per additional quality-adjusted life year (QALY) gained over a 
10-year period. Transition probabilities were derived from patient-level data from 
PREVAIL and a network meta-analysis (NMA) of available trials. Base case analysis 
focused on direct medical costs from the Canadian MoH perspective. Cost data was 
obtained from a variety of Canadian sources, valued in 2015 Canadian dollars. A 
5% discount rate was applied to costs and outcomes. Multiple sensitivity analyses 
were performed. Results: NMA results suggested no difference between enzalu-
tamide and ABI+P for overall survival, but indicated that enzalutamide is superior 
to ABI+P for rPFS (hazard ratio 0.35; credible interval 0.27, 046). The improvement 
in rPFS translated into a longer mean duration of stable disease with enzalutamide 
(36.7 months) than with ABI+P (16.4 months), and greater total QALYs (enzaluta-
mide 2.65; ABI+P 2.23). From the Canadian MoH perspective, enzalutamide had an 
incremental cost-effectiveness ratio (ICER) of $92,690 per additional QALY gained 
versus ABI+P. The ICER was robust over a wide range of sensitivity analyses. In the 
probabilistic sensitivity analysis, the mean ICER was $110,036 per QALY gained 
versus ABI+P, with > 60% of iterations falling below a willingness-to-pay threshold 
of $100,000 per QALY gained. cOnclusiOns: Enzalutamide is considered a cost-
effective treatment option compared to ABI+P in patients with chemotherapy-naïve 
mCRPC after failure of ADT.
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Objectives: In analysis of health state utilities derived from a nivolumab phase 
III clinical trial a statistically significant difference in baseline utilities was noted 
between nivolumab (NIVO) and dacarbazine (DTIC) treatment arms. The aim of 
this study was to analyse and assess possible drivers of this difference in mean 
baseline utility. MethOds: Patient demographics and baseline disease charac-
teristics were compared between treatment arms to identify any variables which 
may be responsible for the observed differences in baseline utilities. All identi-
fied variables were included in a generalised linear model and tested for signifi-
cance differences in a stepwise manner to determine the final predictive utility 
model. Results: Population demographics and baseline disease characteristics 
were generally well balanced between treatment arms, however patients ran-
domised to NIVO were generally of better ECOG performance status (70.5% and 
28.6% for PS 0 and 1 respectively) than those randomised to DTIC (58.2% and 
40.4%). A generalised linear regression model of utility therefore included ECOG 
performance status in addition standard variables age, sex, weight, smoking his-
tory and metastatic stage. After stepwise elimination of non-significant variables, 
ECOG performance status was found to be a strongly significant predictor of health 
state utility (p< 0.000) as was sex (p< 0.000) and age (p= 0.006). Whilst metastatic 
stage remained in the final model specification as these were pre-defined strati-
fication factors, neither was a significant predictor of health state utility (p= 0.724, 
p= 0.493 respectively). cOnclusiOns: ECOG performance status was found to 
be an independent predictor of health state utility in addition to age and sex. As 
such it is critical that any economic evaluation of an intervention in this patient 
population identifies any differences in performance status between intervention 
and comparator arms and seeks to establish the impact any difference may have 
on subsequent results.
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Objectives: Bladder cancer (BC) is a disease with a high recurrence rate, neces-
sitating invasive, repeated treatments that can meaningfully impact patient health-
related quality of life (HRQoL). The goal of this review was to summarize the BC HRQoL 
literature in order to assess the impact of BC by stage and treatment. MethOds: A 
systematic literature search of studies indexed in PubMed was conducted without 
language or publication year limitations. Due to the large volume of literature, subse-
quent review was refined to studies published since 2005, excluding reports utilizing 
single-use HRQoL measures without evidence of validation. Results: A review of 
~1,700 abstracts yielded a final set of 62 peer-reviewed articles (published 2005 – 2014). 
Eleven HRQoL measures (8 disease-specific, 3 generic) were identified (EORTC QLQ-
C30 and SF-36 most commonly used, in 25 and 21 studies, respectively). BC-specific 
modules such as the EORTC QLQ-NMIBC24 were included less frequently, with no 
BC-specific module in more than 8 studies. The majority of studies were of retrospec-
tive, cross-sectional study design. HRQoL impact of radical cystectomy for muscle 
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Objectives: To assess the burden of illness associated with advanced breast cancer 
treated with vinorelbine oral (VinO) or IV (VinIV) from the perspective of patients 
and caregivers in 5 European countries. MethOds: This was an observational, pro-
spective, international, multicentric study. Patients were included in the study at 
the beginning of their 2nd cycle of chemotherapy with vinorelbine and categorized 
in 2 groups depending on whether they are receiving VinO or VinIV. At baseline (V0) 
and at the end of the 2nd cycle of chemotherapy (V1), patients and caregivers were 
asked to complete self-administered questionnaires: SF-12, EORTC-QLQ-C30 (only 
for patients) and burden of illness. Results: At baseline, there were no major dif-
ferences in demographic and clinical characteristics between the two groups. VinIV 
was prescribed monotherapy in 56.9% and 62.5% for VinO. Patients receiving VinO 
were predominantly treated with monotherapy. In addition, as measured with SF-12, 
patients with VinO (n= 128) had, at end of cycle 1 and end of cycle 2, significantly 
more favourable outcomes in physical summary score, role physical, role emotional 
and mental health (all p< 0.05) than those treated with VinIV (n= 51). Trends for 
a better caregiver mental score and social functioning were also observed with 
VinO (cycle 1 and 2; p< 0.10). From a patient perspective, no major difference was 
reported on the burden of illness between the two groups, however, a trend for a 
better “overall impact on daily life” was observed in VinO patients. Major significant 
differences, showing a lower burden of illness with VinO, were also reported from 
caregivers (Social functioning, Overall impact on daily life). cOnclusiOns: Oral 
vinorelbine showed some benefits over the IV form for both patients and caregivers, 
particularly in health related QoL and burden of illness.
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Objectives: Validity and reliability are important characteristics of any instrument. 
Generic instrument are designed for use in any population; however, their validity 
and reliability in particular diseases should be verified to ensure their appropriate-
ness. In this study the authors assessed the validity and reliability of the Medical 
Outcomes Study Short Form–36 (SF-36), a generic instrument, in a population of 
patients with intradural primary spinal cord tumors (IST). MethOds: The SF-36 
was administered to a cohort of patients with IST on an outpatient basis. Symptom-
related data derived from a structured interview and physical examination findings 
were used to classify cases according to the scales of McCormick and Aminoff-
Logue. Construct validity was assessed by determining whether SF-36 scores cor-
relates with the spinal cord tumors scores (McCormick score and Aminoff-Logue 
score) by using the Cuzick nonparametric test for trend. The reliability of the SF-36 
scores was assessed using Cronbach alpha. Results: One hundred patients with 
IST completed the SF-36. Construct validity was demonstrated by confirming the 
hypothesized relationship between SF-36 scales and the scales of McCormick (p _ 
0.003), Aminoff-Logue deambulation subscale (p _ 0.025), Aminoff-Logue micturi-
tion subscale (p _ 0.013), and the Aminoff-Logue defaecation subscale (p _ 0.004). 
Reliability was demonstrated for all eight SF-36 domain scales and the physical 
component and mental component summary scales, in which Cronbach alpha satis-
fied the Nunnally criterion of > 0.85. cOnclusiOns: The SF-36 provides valid and 
reliable data on patients with IST.
PCN247
PrEdiCtors of Utility ovEr timE AmoNg PAtiENts With trEAtmENt-
NAïvE AdvANCEd mElANomA from thE PhAsE 3 ChECkmAtE 066 triAl
Paly V1, Colby C2, Gilloteau I3, Exuzides A4, Briggs A5
1ICON Plc, Morristown, NJ, USA, 2ICON plc, San Francisco, CA, USA, 3Bristol-Myers Squibb, 
Princeton, NJ, USA, 4ICON, plc., San Francisco, CA, USA, 5Institute of Health and Wellbeing, 
University of Glasgow, Glasgow, UK
Objectives: The aim of this analysis was to assess predictors of health-related 
quality of life over time, and to estimate utilities for patients with treatment-naïve 
advanced melanoma in the randomized CheckMate 066 trial comparing nivolumab 
with dacarbazine for use in a cost-effectiveness model (CEM). MethOds: The 
EQ-5D was administered at baseline and every 6 weeks in CheckMate 066 and was 
used to generate index utility scores using the UK time trade-off (TTO) method. 
Covariates were based on a combination of prior analyses from large trial datasets, 
including patient demographic and clinical characteristics, quantitative metrics of 
fit, qualitative/clinical plausibility, and relevance to the CEM. Several longitudinal 
mixed linear models were explored using different covariate sets. Results: This 
analysis included 288 patients and 1,125 visits where the EQ-5D was administered. 
Mean baseline utility score was 0.75 for nivolumab, 0.69 for dacarbazine, and 0.72 
across both treatment arms. The final model included baseline utility (to adjust 
for imbalance between treatment arms), progression status (pre/post), days until 
death or end of follow-up (< 30 days/30+ days), and treatment arm. Parameter esti-
mates in the model were 0.603 for baseline utility (P< 0.001), −0.074 for progression 
status (P< 0.001), −0.022 for < 30 days left (P= 0.092), and −0.069 for treatment arm 
(dacarbazine vs nivolumab; P= 0.008). When implemented in the CEM, the utility 
estimate for the pre- and post-progression states were 0.802 and 0.728, respec-
tively (applying nivolumab as the treatment arm). A decrement for the month 
preceding death was applied using the estimate for < 30 days until death or end 
of follow-up (−0.022). cOnclusiOns: These results showed that baseline utility, 
progression, < 30 days until death or end of follow-up, and treatment arm are all 
predictors of utility over time, which is consistent with prior work in melanoma. 
As data mature, these analyses will be replicated in this and other nivolumab 
trials.
